Protollin Alzheimer's Disease Preventive Vaccine for Nasal Use Starts Trial

CompilationTom Lee

After years of preparation, scientists at Brigham and Women's Hospital are preparing to start a clinical trial that will evaluate the effectiveness of intranasal vaccines in preventing Alzheimer's disease (AD)

The candidate vaccine uses the immunomodulator Protollin and works by activating monocytes in the lymph nodes of the neck.

If this new immunological method succeeds, it is an important milestone in the treatment of Alzheimer's disease.

The initial trial will involve 16 human participants who have been diagnosed with early symptoms of Alzheimer's disease

At the end of July this year, Tianjing Biotechnology announced that Protollin, a new drug under development for the treatment of Alzheimer's disease, was approved by the FDA to initiate a phase 1 clinical trial

Dr.

It is worth noting that this is not the first time that Protollin has been used in human treatment

Reference source: Nasal Vaccine Starts Trial to Protect Against Alzheimer's